Tesamorelin

The Complete Guide to Dosage, Benefits, and Research

1. Tesamorelin Dosage Chart | Quick Breakdown

Purpose	Dosage	Frequency	Administration
HIV-related Lipodystrophy	1.4 mg (EGRIFTA SV)	Once daily	Subcutaneous injection
Research/Off-label use	1-2 mg	Once daily	Subcutaneous injection

2. What is Tesamorelin?

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue. Key points:

44 amino acid polypeptide
Modified N-terminal for improved stability and pharmacokinetics
FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy
Marketed under the brand name Egrifta/Egrifta SV

3. Tesamorelin Mechanism of Action

Tesamorelin works through several mechanisms:

1 Activates GHRH receptors in the pituitary gland
2 Stimulates synthesis and release of growth hormone
3 Increases production of insulin-like growth factor-1 (IGF-1)
4 Promotes lipolysis and reduces visceral adiposity
5 Influences glucose and lipid metabolism

4. Research Applications and Potential Benefits of Tesamorelin

Tesamorelin and HIV-related Lipodystrophy

Reduces excess abdominal fat
Improves body composition

Tesamorelin and Metabolic Health

Potential benefits for insulin resistance
Being studied for nonalcoholic fatty liver disease (NAFLD)

Tesamorelin and Athletic Performance

Potential for improved body composition
May support muscle growth and fat loss

Tesamorelin and Cognitive Function

Preliminary research suggests potential cognitive benefits

5. Tesamorelin Dosage Guide

Dosing Tesamorelin for HIV-related Lipodystrophy

FDA-approved dose: 1.4 mg of EGRIFTA SV once daily

Dosing Tesamorelin for Research/Off-label Use

Typical doses range from 1-2 mg once daily

6. How to Mix and Administer Tesamorelin

Reconstitution Procedure (for EGRIFTA SV)

1 Use only the provided Sterile Water for Injection to reconstitute
2 Reconstitute 1 vial with 0.5 mL of diluent
3 Mix by rolling the vial gently for 30 seconds (do not shake)
4 Use immediately after reconstitution

7. Tesamorelin Administration Methods

Tesamorelin is administered via subcutaneous injection only:

Inject into the abdomen
Rotate injection sites
Do not inject into scar tissue, bruises, or the navel

8. Tesamorelin Combinations and Interactions

May interact with insulin and oral hypoglycemics
Caution advised when used with cortisone, simvastatin, ritonavir, or prednisone
Potential interactions with other growth hormone-related compounds

9. Where to Buy Tesamorelin Online | 2024 Edition

Tesamorelin is a prescription medication and should only be obtained through licensed pharmacies with a valid prescription.

10. Is Tesamorelin Safe?

Generally considered safe but with some considerations:

Common side effects: injection site reactions, arthralgia, pain in extremities
Potential for glucose intolerance and insulin resistance
Contraindicated in patients with active malignancy
Caution advised in patients with diabetes or history of pituitary disorders

11. Is Tesamorelin Legal?

FDA-approved for HIV-related lipodystrophy in the United States
Prescription-only medication
Banned by WADA for competitive athletes (falls under S2.2.4 of the Prohibited List)

12. Tesamorelin Storage and Handling

Store lyophilized powder at room temperature (20°C to 25°C or 68°F to 77°F)
Protect from light
Use immediately after reconstitution
Do not freeze reconstituted solution

13. Frequently Asked Questions (FAQ)

How long does it take to see results with tesamorelin?

Can tesamorelin be used for bodybuilding?

Is tesamorelin safe for long-term use?

14. Tesamorelin Dosage | Final Verdict

Tesamorelin is a potent GHRH analogue with proven benefits for HIV-related lipodystrophy. Its potential extends to other areas of metabolic health, but more research is needed. The standard dose of 1.4 mg daily (EGRIFTA SV) is well-established for its approved use. Off-label or research applications may use different dosing protocols. As with any peptide hormone, use should be under medical supervision with careful consideration of individual health factors and potential risks.